Trial Profile
A phase II study of Xelox [capecitabine] in locally advanced or metastatic gastric cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2018
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 23 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jan 2008 Status changed from recruiting to in progress.
- 27 Dec 2007 The expected completion date for this trial is now 1 Jul 2007.